A Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Oral Doses Of PF-03716539 In Healthy Adult Subjects

PF-03716539 10 mg oral solution, single dose

PF-03716539 25 mg oral solution, single dose

PF-03716539 3 mg oral solution, single dose

Placebo for 3 mg, 10 mg and 25 mg of PF-03716539 (single dose)

PF-03716539 100 mg oral solution, single dose

PF-03716539 200 mg oral solution, single dose

PF-03716539 50 mg oral solution, single dose

Placebo for 50 mg, 100 mg and 200 mg of PF-03716539 (single dose)

Midazolam 1 mg IV, single dose

Midazolam 1 mg IV, single dose plus PF-03716539 100 mg oral solution, single dose

Midazolam 1 mg IV, single dose plus PF-03716539 50 mg oral solution, single dose

Darunavir 600 mg tablet twice daily for 9 days (Days 1-9)

Darunavir 600 mg tablet, single dose plus PF-03716539 50 mg oral solution, single dose (Day 10)

Maraviroc 150 mg tablet once daily for 6 days (Days 1-6)

Maraviroc 150 mg tablet, single dose plus PF-03716539 100 mg oral solution, single dose (Day 7)

Maraviroc 225 mg tablet once daily for 6 days (Days 1-6)

Maraviroc 225 mg tablet, single dose plus PF-03716539 200 mg oral solution, single dose (Day 7)